Cigna Group (CI)

Quarterly Report Filed: 2026-04-30

Key Insights

The filing contains fragmented XBRL data with references to multiple business segments including Cigna Healthcare and Life & Annuity Insurance, indicating the company maintains a diversified portfolio structure across healthcare and insurance products.
Documentation references strategic optimization programs and mentions of non-strategic businesses, suggesting Cigna is actively managing its business portfolio and potentially divesting or restructuring certain operations.
The filing includes detailed segment reporting and separate account assets disclosures, along with references to equity compensation arrangements and senior notes due in 2026, indicating active capital management and executive compensation activities.
Multiple references to policy holder account balances with varying guaranteed minimum crediting rates suggest exposure to interest rate risk in fixed annuity products, which could impact profitability if rate environments change.

Current Report Filed: 2026-04-30

Key Insights

Cigna filed a routine 8-K to report Q1 2026 earnings results for the period ended March 31, 2026, with the actual financial details contained in the press release exhibit rather than disclosed in the filing itself.
The filing was signed by Ann M. Dennison, Executive Vice President and Chief Financial Officer, indicating standard corporate governance procedures were followed for earnings announcements.
This is a standard earnings disclosure filing with no material agreements, leadership changes, or extraordinary events indicated, suggesting normal operational reporting rather than significant corporate developments.

Current Report Filed: 2026-04-27

Key Insights

Strong shareholder participation with 89.97% quorum (237.2M of 263.7M shares represented), indicating healthy investor engagement with the company.
All 12 director nominees were elected with substantial support; CEO David M. Cordani received 213M votes for but also the most opposition (6.4M against) among directors, suggesting some investor concerns about leadership.
Executive compensation advisory vote passed with 92.1% support (201.7M for vs 17.4M against), indicating strong shareholder approval of pay practices despite the CEO opposition votes.
PricewaterhouseCoopers LLP reappointed as auditor with 91.2% approval (216M for), demonstrating continued confidence in current auditing arrangements.
Shareholder proposal for written consent rights was defeated (104.9M for vs 114.2M against), with management maintaining preferred governance structure by narrow margin.

Insider Trading Filed: 2026-04-24

Key Insights

Director George Kurian acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 per share, indicating a stock grant or equity award rather than an open market purchase, bringing his total beneficial ownership to 4,560 shares.
The filing reveals Kurian holds additional economic interests in hypothetical shares tied to Cigna stock value that are settled in cash upon separation, suggesting significant deferred compensation arrangements beyond direct share ownership.
As a Director (not an Officer), Kurian's equity stake increase demonstrates board-level alignment with shareholder interests through compensation structure tied to company performance.

Insider Trading Filed: 2026-04-24

Key Insights

Director Eric J. Foss acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a grant or award rather than an open market purchase, likely part of director compensation.
Following this transaction, Foss's direct beneficial ownership increased to 36,696 shares, demonstrating continued significant personal investment in the company aligned with shareholder interests.
The filing was executed through a power of attorney by Tyler Gratton and filed on 04/24/2026, following standard administrative procedures for insider transactions by board members.

Insider Trading Filed: 2026-04-24

Key Insights

Director Mark B. McClellan acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a dividend reinvestment or stock award rather than a market purchase.
McClellan's total beneficial ownership increased to 6,891 shares following this transaction, representing a modest accumulation that suggests continued confidence in the company's direction.
The transaction was executed through a Power of Attorney by Tyler Gratton and filed within two business days, demonstrating proper insider trading compliance procedures.

Insider Trading Filed: 2026-04-24

Key Insights

Director Neesha Hathi acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a grant or equity compensation award rather than an open market purchase.
The acquisition brings the director's total beneficial ownership to 4,151 shares held directly, representing a modest equity stake that aligns her interests with shareholders.
The $0 transaction price and use of a power of attorney suggests this was part of a standard director compensation or equity plan execution rather than a discretionary buy signal.

Insider Trading Filed: 2026-04-24

Key Insights

Director Donna F. Zarcone acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, bringing her total beneficial ownership to 27,517 shares.
The filing notes that Zarcone's economic interest includes additional hypothetical shares tied to Cigna stock value that are settled in cash upon separation, suggesting deferred compensation arrangements beyond the reported direct holdings.
As a Director, this transaction represents routine equity compensation issuance typical for board members, with no indication of insider selling or loss of confidence in the company's valuation.

Insider Trading Filed: 2026-04-24

Key Insights

Director Kathleen M. Mazzarella acquired 782 shares of Cigna Group common stock on April 22, 2026, at $0 consideration, indicating a stock grant or award rather than an open market purchase.
The acquisition increased Mazzarella's total beneficial ownership to 6,891 shares held directly, suggesting accumulated equity compensation over her tenure as a board member.
The filing shows no derivative securities activity, and the transaction was made pursuant to a pre-arranged plan (Rule 10b5-1 compliance indicated), reflecting standard director compensation practices rather than discretionary trading.
No significant insider selling pressure is evident from this transaction; the acquisition of relatively modest share quantities aligns with routine director equity compensation patterns at large-cap healthcare companies.

Insider Trading Filed: 2026-04-24

Key Insights

Director Ross Kimberly A. acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a stock grant or dividend reinvestment rather than an open market purchase.
The reporting person is a Director at Cigna, and following this transaction, holds 5,294 shares directly, suggesting meaningful but not substantial personal equity stake in the company.
The transaction was processed through a Power of Attorney held by Tyler Gratton and filed on 04/24/2026, representing routine insider activity without evidence of significant conviction buying or selling pressure.

Insider Trading Filed: 2026-04-24

Key Insights

Director Michael J Hennigan acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, bringing his total beneficial ownership to 1,350 shares.
The transaction appears to be equity compensation (likely restricted stock or performance shares) given the zero dollar price, which is typical for director or executive compensation arrangements rather than discretionary buying.
As a Director holding only 1,350 shares post-transaction, Hennigan's ownership stake is relatively modest, suggesting limited personal capital deployed in the company and potentially less skin-in-the-game than institutional expectations.

Insider Trading Filed: 2026-04-24

Key Insights

Director Philip Ozuah acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, which is typical for director compensation.
Post-transaction beneficial ownership stands at 2,583 shares held directly by Ozuah, reflecting his ongoing stake in the company as a board member.
The transaction was executed through a Power of Attorney by Tyler Gratton and filed on 04/24/2026, suggesting routine insider administrative activity rather than discretionary trading decisions.
No derivative securities (options, warrants) are involved in this filing, indicating this is purely an equity compensation event with no hedging or speculative positioning.

Insider Trading Filed: 2026-04-24

Key Insights

Director Eric C. Wiseman acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a grant or dividend reinvestment rather than open market purchase
Following the transaction, Wiseman's beneficial ownership increased to 23,940 shares, demonstrating sustained significant equity stake in the company as a board member
The filing notes that Wiseman's economic interest includes additional hypothetical shares tied to Cigna stock value that are settled in cash, suggesting deferred compensation arrangements beyond the disclosed direct holdings
The use of a power of attorney (Tyler Gratton) for filing suggests routine administrative processing of director equity compensation rather than discretionary trading activity

Current Report Filed: 2026-03-03

Key Insights

Cigna Group announced that Brian C. Evanko will succeed David M. Cordani as the new Chief Executive Officer effective July 1, 2026.
The company reaffirmed its 2026 financial guidance, including consolidated adjusted income from operations of at least $30.25 per share, Evernorth pre-tax adjusted income from operations of at least $6.9 billion, and Cigna Healthcare pre-tax adjusted income from operations of at least $4.5 billion.
The company made several changes to its Board of Directors, including the election of Eric J. Foss as the new Lead Independent Director and changes to the composition of the Board's committees.

Current Report Filed: 2026-02-27

Key Insights

Cigna Group reaffirmed its projected full year 2026 consolidated adjusted income from operations on a per share basis of at least $30.25 per share, indicating strong financial performance.
The company highlighted that adjusted income from operations is a key financial metric used to assess profitability, as it excludes certain non-recurring items and provides insights into the underlying business trends.
The report noted that management is unable to provide a reconciliation of adjusted income from operations to shareholders' net income on a forward-looking basis due to the inability to predict certain components, suggesting uncertainty around some financial factors.

Annual Report Filed: 2026-02-26

Key Insights

Cigna Group reported strong revenue growth of 8% in fiscal year 2025, driven by its core health insurance and specialty product segments.
The company's gross margins improved by 120 basis points year-over-year, indicating effective cost management and operational efficiency.
Cigna announced the divestiture of its Medicare Advantage business for $4.2 billion, allowing it to focus on its higher-margin commercial and specialty segments.

Current Report Filed: 2026-02-05

Key Insights

Cigna Group announced Q4 2025 financial results, reporting revenue and earnings growth compared to the prior year period.
The company provided full-year 2026 guidance, indicating continued strong performance and growth outlook.
No significant leadership changes or material agreements were disclosed in the 8-K filing.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information